Introduction
The presence of a p53 mutation in the germline is associated with a tumor predisposition in men and mice (Donehower et al., 1992; Kleihues et al., 1997; Malkin et al., 1990; Varley et al., 1997) . Half of the aected families meet the clinical criteria of the LiFraumeni tumor syndrome (Li et al., 1988) in which cosegregation of p53 germline mutations with tumor predisposition has been discovered ®rst (Malkin et al., 1990) . Even though the p53 mutations are present in all somatic cells only certain tissue types seem to be predisposed to develop cancer. The most common tumors being sarcoma (24%), breast cancer (24%) and brain tumors (13%) , suggesting that selection for p53 inactivation plays an important role early in the development of these tumor types. This is supported by the fact that colon cancer is rarely observed (2%) in the context of a germ line mutation, even though sporadic colon cancer selects for p53 mutations in 50% of the cases, but late in progression. The distribution and spectrum of p53 mutations found in the germ line follow the pattern determined for sporadic tumors (Hollstein et al., 1996) . Most missense mutations in the evolutionary conserved areas of the p53 gene lead to loss of transactivation, and thus, corrupt important p53-mediated tumor suppressing functions induced by various types of cellular stress (Graeber et al., 1996; Kastan et al., 1991; Zindy et al., 1998 ) that normally prompt cell cycle arrest or apoptosis (reviewed in Levine, 1997) . Some mutations however, exhibit cell-type and promoter-dependent dierences in their phenotype for functions related to transactivation (Crook et al., 1994; Forrester et al., 1995; Friedlander et al., 1996) . A transdominant eect can be observed if the oligomerization domain remains intact and allows the p53 mutant to sequester wild-type p53 into an inactive complex (CheÁ ne et al., 1997; Shaulian et al., 1993) .
Although p53 mutants typically lose their ability to transactivate p53 target genes certain p53 mutants have been reported to exhibit gain-of-function activity. This additional phenotype comprises oncogenic properties such as increased tumorigenic potential of a mouse ®broblast cell line in nude mice, enhanced plating eciency of SAOS-2 cells (Dittmer et al., 1993) , or disruption of spindle checkpoint control in human ®broblasts upon challenge with a spindle cell depolimerizing agent (Gualberto et al., 1998) . Recently, Liu et al. (2000) reported a mouse model with a metastatic tumor phenotype especially for osteosarcomas upon introduction of a p53 hot-spot mutant into the endogenous p53 locus (knock-in of R172H, corresponding to human R175H). It has been proposed that missense mutations in the core DNA-binding domain, as compared to other mutations, may have a more penetrant tumor phenotype and lead to an earlier onset in life, particularly for brain tumors and breast cancer (Birch et al., 1998; Vital et al., 1998) . The relevance of gain-of-function activity for tumorigenesis is unknown and most likely cell type dependent. It is dicult to assess the signi®cance of gain-of-function activity on tumor predisposition in humans, because of the small numbers for p53 germ line mutations and the heterogeneity of the genetic background in the human population.
Here we set out to test the gain-of-function activity in regard to tumor penetrance and cell type speci®city within a mouse brain tumor model. A transgenic mouse line was made expressing the human p53 mutant Y236D in astrocytes using the promoter of the glial ®brillary acidic protein (GFAP) gene. This unique mutant was found in the germline of a family as reported before and cosegregated with a brain tumor syndrome (LuÈ bbe et al., 1995) . In only two generations with ®ve carriers, four early onset (427 years) brain tumors developed, three of astrocytic origin and one that was never classi®ed. The high tumor penetrance and the apparent tropism to the brain made this mutant a good candidate to test. Brain tumors were induced transplacentaly with ethylnitrosourea (ENU, 25 mg/kg BW). Glial tumors arose in 18% (7/39) of GFAP-Y236D (Tg21) transgenic p53 +/7 mice, while the incidence in p53 +/7 mice was 27% (11/40) (P40.3). In contrast, the mean brain tumor latency was signi®cantly shorter in Tg21/p53
than in p53 +/7 mice (P=0.039). No dierence was observed in survival due to extracerebral tumors associated with p53-de®ciency. It follows that expression of Y236D leads to acceleration of tumor progression but does not confer gain-of-function activity resulting in higher tumor penetrance in this brain tumor model. The endogenous p53 wild-type allele was lost in all brain tumors from both genotypes, suggesting a growth advantage due to the transdominant eect of Y236D early in the progression of neoplastic cells. This models the human disease well, since p53 mutations are frequently associated with loss of the wild-type allele in both sporadic and germ line mutation associated brain tumors (LuÈ bbe et al., 1995; Vital et al., 1998; von Deimling et al., 1992) .
Results

Transgenic mice expressing Y236D in astrocytes
We made transgenic mice expressing the human p53 mutant Y236D under the control of the regulatory elements of the GFAP gene that direct expression to astrocytes (Figure 1a) . Two founder mice resulted from microinjections. One mouse turned out to be mosaic, because none of 53 ospring analysed carried the transgene. Southern blot analysis of line Tg21 [BDF2-TgN(GFAP-hp53)21moh] revealed an intact transgene, with a single integration site and a copy number in the range of two (Figure 1b) . Expression levels of the transgene in the brain were relatively low and not detectable by Northern blot analysis using 10 mg of total RNA, while the signal for GFAP expression was strong (data not shown). Detection by RT ± PCR disclosed expression of the transgene in the brain (Figure 1c) . Additionally, some expression was detectable in the spleen and testes. Low expression levels of Y236D in the cells were desirable since normal p53 levels in cells are low.
Induction of transgene expression in astrocytes by cryo-lesions
In order to test the functionality of the GFAPregulatory elements on the expression of Y236D the GFAP gene was induced by cryo-lesions. Injury or in¯ammation of the brain will induce GFAP expression and simultaneously should upregulate expression of the transgene (Mucke et al., 1991) . Indeed, focal injury by cryo-lesions induced expression of Y236D within 16 h while expression of GFAP was detectable after 48 h as determined by immunohistochemistry (Figure 2 ). Double staining of the lesioned brains for human p53 and GFAP con®rmed exclusive expression of the transgene in astrocytes. In brains of untreated transgenic mice immunohistochemical analysis revealed only occasional cells (51%) positive for Y236D in the cortex and the hippocampal ribbon. Slightly higher numbers of p53 positive cells were found in substantia nigra, white matter and corpus callosum. The treatment did not induce endogenous wild-type p53 detectable by immunohistochemistry. Note, expression levels of wild-type p53 in normal tissues are undetectable by immunohistochemistry due to the short halflife of the protein.
Reduced latency of brain tumor development but no increased frequency in Tg21/p53 +/7 mice Brain tumors were induced by ENU exposure in utero.
Within the observation time of 58 weeks the incidence of brain tumors in Tg21/p53 +/7 mice was 18% (7/39), while the incidence seen in p53 +/7 mice was 28% (11/ 40). Thus, expression of Y236D certainly did not increase the tumor frequency (P40.3, Chi-square test) (Table 1) . However, the mean tumor latency was 11.7 weeks shorter in Tg21/p53 +/7 mice with a mean of 19.9 weeks as compared to p53 +/7 mice with a mean latency of 31.6 weeks (P=0.039, Mann Whitney U-Test) (Table 1, Figure 3a ). All brain tumors arising in Tg21/p53 +/7 mice displayed nuclear expression of Y236D in 1 ± 50% of the cells (Figure 4) , suggesting that the transdominant eect might be responsible for the reduced brain tumor latency, keeping with our previous demonstration of a transdominant eect of Y236D over murine wild-type p53 in vitro and in vivo (CheÁ ne et al., 1999; Hegi et al., 2000) . Subsequent microsatellite analysis of the brain tumors at the loci D11Mit90 and D11Mit279, each within a few cM of the p53 gene on chromosome 11, revealed loss of the wild-type allele (DBA/2-allele) in both, p53 +/7 and Tg21/p53 +/7 mice, while the allele harboring the p53k/o gene was retained (Figure 5a ). Thus, the transdominant eect of Y236D is likely to be important early in development of these mouse brain tumors and re¯ects observations in human astrocytic tumors in which p53 mutations are associated with LOH on chromosome 17p (von Deimling et al., 1992) .
None of the mice representing other p53-genotypes had to be killed due to the development of brain tumors (Table 1) . However, all ENU exposed Tg21/ p53 7/7 and p53 7/7 mice had to be killed at a mean age of 9.2 weeks ( Figure 3b ) due to the development of thymic lymphoma. At this early age there was no histological evidence of neoplastic lesions in the brain.
Brain tumor types
Most tumors in this study were of glial origin, based on morphology and expression of GFAP, a marker for astrocytic cells. Tg21/p53 +/7 mice developed tumor entities resembling the features of glioblastoma (n=1) with high mitotic activity, necrosis and in®ltration of the adjacent brain parenchyma, and anaplastic astrocytoma (n=6), while p53 +/7 mice were aected by one glioblastoma, three anaplastic astrocytomas, four glial tumors, and three gangliogliomas. Gangliogliomas are well dierentiated mixed glial-neuronal tumors (Kleihues and Cavenee, 2000) . All seven brain tumors in Tg21/p53 +/7 mice and six of 11 brain tumors presenting in p53 +/7 mice during the observation period were visible upon macroscopic examination of the brain.
After ®nal necropsy at 58 weeks, histologic evaluation revealed gangliogliomas located in the temporal lobe close to the corpus callosum of two ENU treated Tg21/p53 +/7 and two p53 +/7 mice. Similar lesions were detected in eight of 40 (20%) treated Tg21/p53 +/+ mice, while of the 37 untreated Tg21/p53 +/7 mice none showed any histological evidence of brain tumors at this age.
Microsatellite analysis in brain tumors
Brain tumors were microdissected and analysed for LOH at chromosomal regions homologous to loci commonly lost in human astrocytic brain tumors. With the exception of markers on chromosome 11, where p53 resides, LOH was uncommon. All 12 brain tumors analysed had lost the wild-type p53 allele as determined at the markers D11Mit90 and D11Mit279 (Figure 5a ) that are within a few cM of the p53 gene, while the proximal marker D11Mit82 located within 2 cM of the egfr gene was retained in one case, and not informative (Toggas et al., 1994) ,¯anked 5' by the simian virus SV40 late gene splice site (v) and 3' by the polyadenylation signal (*); the ®rst two ATG's of exon 1 were altered into TTG's. (b) Southern blot analysis of BamHI restricted DNA derived from a wild-type (wt) mouse, a transgenic (Tg) littermate, and from a human glioma cell line (CL) with intact p53, using a mouse full length p53 cDNA probe. The approximate sizes of the lamda marker (M) are indicated on the left. The transgene displays the expected size of 1.8 kb (arrow) and was estimated to be present in ca. two copies per cell. (c) Expression of Y236D in dierent organs of transgenic mice was determined by RT ± PCR after DNase treatment (RT-ctr, without reverse transcriptase). The ampli®ed, spliced transcript of Y236D has an expected length of 338 bp and the unspliced transcript of 425 bp (M, 100 bp marker). GFAP expression was restricted to the brain. The amplicon size for b-actin is 549 bp. Expression of Y236D was detectable in the brain, but also in the spleen and to a lesser extent in testes in another case. One brain tumor exhibited LOH at the p16/p19ARF locus (Mts-1), and none showed evidence of LOH at a marker within the Rb-1 gene (D14Nki). Homologous regions of human chromosome 10 that are frequently lost in human gliomas were analysed: The markers D19Mit13 and D19Mit80 (Figure 5b ) in the vicinity of the pten gene on mouse chromosome 19 (Di Cristofano et al., 1998) displayed LOH for both markers in two of eight (25%) informative cases. Only eight of 12 cases were informative and retained heterozygosity at the markers D7Mit291 and D7Mit333 located on mouse chromosome 7 representing the homologous region for DMBT1 located on human chromosome 10(q25.3-q26.1) (Mollenhauer et al., 1997) .
Development of extracerebral tumors
Although ENU is a neurocarcinogen in mice (Denlinger et al., 1974) , and most brain tumors arose before clinical manifestation of other tumor types, the main cause of death was extracerebral tumor predisposition associated with p53 de®ciency (+/7 or 7/7) ( Figure  3b ). The distinct brain tumor latency between Tg21/ Figure 2 Induction of Y236D and GFAP by cryo-lesions in Tg21-mice. Cryo-lesions in the brain result in necrosis (marked with asterisks) (a) (HE, hematoxylin/eosine staining), and subsequently induce gliosis (b,d) comprising reactive astrocytes expressing high levels of GFAP (double immunohistochemistry for GFAP, brown, and human p53, red). In treated transgenic mice, expression of Y236D in astrocytes is upregulated (d). Double staining for p53 and GFAP reveals exclusive nuclear expression of Y236D in astrocytes of Tg21-mice, but not wild-type mice (wt). In untreated Tg21-mice (c) nuclear expression levels of Y236D are generally low and only detectable in a few cells by immunohistochemistry , n=4) . Thus, the real dierence in mean brain tumor latency should likely be larger than observed due to the problem of early lethal tumors associated with germline p53 de®ciency.
The cumulated tumor incidence after 1 year and the spectrum of extracerebral tumors is summarized in Table 2 . The ENU treatment induced mostly lung and hepatocellular carcinomas in mice with a p53 +/7 or a p53 wild-type background. The ratio of lymphoma aicted animals did not change upon ENU treatment in p53 +/7 mice. In contrast, all p53 7/7 mice had to be killed between the age of 7 and 13 weeks (median 9.2), due to the development of thymic lymphomas. Remarkably, in p53 7/7 mice all lymphomas were of thymic origin while mice with other p53-genotypes developed peripheral lymphomas with one exception. As expected from expression analysis (Figure 1b) the presence of the transgene did not alter survival and tumor spectrum of extracerebral tumors in p53 +/7 and p53 7/7 mice, respectively ( Figure 3b and Table 2 ). In addition, transplacental exposure to ENU induced malignant nerve sheath tumors (mPNST) in the spinal cord of Tg21/p53 +/7 and p53 +/7 mice. Microsatellite analysis on chromosome 11 revealed loss of the p53 wild-type allele in a subset of them.
Discussion
Reduced latency but no gain-of-function in regard to tumor penetrance
Expression of Y236D in astrocytes of p53 +/7 mice signi®cantly reduced the mean brain tumor latency by 11.6 weeks from 31.6 to 19.9 (P=0.039) (Figure 3a) . In contrast, expression of Y236D had no signi®cant impact on brain tumor incidence, and rather reduced than increased the frequency, with 18% (7/39) in Tg21/ p53 +/7 mice as compared to 28% (11/40) in p53 +/7 mice (P40.3). Furthermore, Y236D was expressed in all respective brain tumors at various degrees. Taken together, Y236D most likely exerted a dominant negative eect on endogenous wild-type p53 but displayed no gain-of-function activity in regard to brain tumor penetrance. This conclusion is in line with our previous ®ndings showing a transdominant eect on human p53 in vitro (CheÁ ne et al., 1999) and on murine wild-type p53 in vivo using a retroviral expression system in neuroectodermal transplants . The endogenous wild-type p53 allele was lost in astrocytic tumors derived from p53 +/7 and also Tg21/ p53 +/7 mice. Thus, the eect of Y236D provided a growth advantage relatively early in the development of these tumors, consequently reducing the tumor latency. Transdominant inactivation of most cellular p53 by Y236D may have accelerated genetic instability required to allow for non-disjunction, the most common genetic alteration by which second-hit mutations occur in mice (Luongo et al., 1994) . The association of p53 mutations with loss of the wild-type allele is well known from human astrocytic brain tumors and represents one of the ®rst genetic alterations detectable (von Deimling et al., 1992) . Frequent loss of the wild-type allele is also reported from brain tumors associated with p53 germline mutations, including the family in which Y236D was originally detected (LuÈ bbe et al., 1995; Vital et al., 1998) .
Although Y236D exerted no gain-of-function in regard to tumor penetrance in p53 +/7 mice, we cannot exclude the possibility of a gain-of-function eect resulting in acceleration of progression. In other words, the rate of initiation (carcinogen-induced mutations) and the rate of LOH might have been the same, but followed by more rapid progression resulting in earlier onset of visible tumors. The gain-of-function eect would be more pronounced after elimination of the endogenous p53 allele (LOH), since Y236D is sequestered into complexes with murine p53. Unfortunately, we can not dierentiate between a gain-of-function activity and transdominance of Y236D due to the dramatically reduced life span of p53 7/7 mice in this experiment. In experimental models gain-of-function activity of certain p53 mutants have been de®ned in regard to dierent biological endpoints, such as loss of spindle check point control upon challenge with spindle depolimerizing agents, increased tumorigenic potential of cell lines, and metastatic phenotype in mice. In humans a higher tumor penetrance associated with certain p53 germline mutations has been postulated as a gain-of-function phenotype. However, underlying molecular mechanisms are unknown.
Low expression of Y236D in astrocytes of Tg21/ p53 +/7 mice followed by LOH during tumor progression represents an interesting model for the evolution of human astrocytomas in which p53 mutations associated with LOH depict an important early feature (von Deimling et al., 1992) . In contrast to other transgenic mice expressing a p53 mutant (Lavigeur et al., 1989) , the expression levels in Tg21 are not sucient to overcome expression of both endogenous wild-type p53-alleles. Therefore Tg21/p53 +/7 mice provide a useful tool to investigate the role of the dominant negative eect early in the development of astrocytomas.
p53 in progression of astrocytic brain tumors p53-de®cient mice as well as mice with a knock-in of a p53 hot-spot mutation rarely develop brain tumors in spite of the apparent importance of p53 mutations in human astrocytomas (Harvey et al., 1993; Liu et al., 2000) . However, predisposition to early lethal extracerebral tumors represents a major drawback for brain tumor research. Using a neurografting paradigm, we previously reported a brain tumor model that circumvents these caveats. Transplantation of p53-de®cient neuroectodermal cells into wild-type mice . Taken together, reduced p53 gene dosage in astrocytes is not sucient to initiate the development of astrocytic brain tumors in mice. However, reduced p53 gene dosage is critical to allow progression to malignant tumors after initiation with ENU (Table 1) . Expression of Y236D in astrocytes of p53 +/7 mice signi®cantly shortened the latency, but rather reduced than increased the brain tumor frequency. In the skin initiation/progression model developed by Balmain (Kemp et al., 1993) a reduced frequency of benign tumors was observed in p53 7/7 mice as compared to p53 +/7 mice, while malignant progression was greatly enhanced. They hypothesized that the level of treatment induced damage in p53 7/7 target cells that are unable to arrest in G1 to allow for repair, may have caused more initiated cells to die. Such increased sensitivity to DNA damage may also characterize Tg21/p53 +/7 astrocytes in which endogenous p53 is further reduced through transdominant inactivation by Y236D.
The importance of p53 in progression of glial tumors in mice is in line with an earlier study by Oda et al. (1997) . They reported a high frequency (70%) of astrocytic brain tumors in p53 7/7 mice as early as at 8 weeks of age after transplacental ENU exposure. The incidence of astrocytomas in p53 +/7 mice was low (3.6%) and always linked with loss of the wild-type p53 allele; again demonstrating the necessity to inactivate the p53-pathway early in progression. Thus, the mouse strain used in our study seems to be more susceptible to ENU-treatment. Susceptibility to ENU-induced neurocarcinogenesis or extracerebral carcinogenesis greatly depends on mouse strain, dose, and timing of treatment during development [ (Denlinger et al., 1974; Harvey et al., 1993) (http://www.informatics.jax.org/ straingrid.html)].
Cooperating genetic alterations
In an attempt to evaluate whether genetic alterations observed in human astrocytomas were also present in the murine tumors obtained in this study, genetic regions homologous to human genes, including EGFR, PTEN, DMBT1, Rb-1, and p16/p14ARF were analysed for LOH (Ekstrand et al., 1991; Fulci et al., 2000; Hegi et al., 1997; Ichimura et al., 1996; Maier et al., 1998; Mollenhauer et al., 1997; Steck et al., 1997) . Deletion of the chromosomal region containing the pten gene was lost in two brain tumors (25%) and might indicate mutational inactivation of pten on the retained allele. In general, deletions or ampli®cations were infrequent. This result is not surprising however, because alterations at these loci are more frequently associated with glioblastoma, the most malignant form of astrocytic tumors that was only observed twice in this study. Furthermore, most genetic alterations known are rarely observed in the presence of a p53 mutation (Kleihues and Ohgaki, 1999) . Unfortunately, little is known about genetic alterations that cooperate with p53 mutations in astrocytomas (Hermanson et al., 1996; Rosenberg et al., 1996) .
Several attempts have been made to look for genetic alterations cooperating with p53 de®ciency to induce brain tumors in mice. Astrocytoma formation induced by expression of v-src in astrocytes was neither increased nor accelerated in p53 +/7 mice (Maddalena et al., 1999) . The v-src gene product is able to activate the EGFR signal transduction pathway (Sato et al., 1995) . The lack of cooperation in this experiment is in accordance with human data showing that EGFR ampli®cation or overexpression and p53 mutations are mutually exclusive events (Watanabe et al., 1996) . In contrast, cooperation was recently shown for inactivation of both p53 and Rb-1 using the Cre-LoxP system, and expressing the Cre recombinase under the control of the GFAP-promoter (Marino et al., 2000) . Mice developed early onset medulloblastomas. However, no glial tumors were observed in this mouse model which might have been precluded by the reduced life span.
Despite the generally low susceptibility of mice to develop tumors of the CNS (Fraser, 1971 ) introduction of mutant p53 allows to experimentally induce astrocytomas that model characteristic features of pathogenetic pathways involved in the development of human astrocytomas. This mouse astrocytoma model provides a useful tool to further investigate genetic alterations involved in the p53 pathway and to test neurocarcinogenicity of chemical compounds. However, in order to avoid extracerebral tumors associated with p53 de®ciency it would be useful to breed the Tg21-mouse to a conditional p53 knock-out for astrocytes that has been published recently (Marino et al., 2000) .
Materials and methods
Plasmid construction and generation of transgenic mice
The human p53 mutant Y236D (CheÁ ne et al., 1999) was cloned into the BamHI site of the pBS-SK+ vector (Stratagene). NotI-adaptors (Pharmacia) were added on both sides in order to clone the p53 mutant into the NotI-sites of exon 1 of a modi®ed 17 kb construct of the GFAP gene comprising the entire intron/exon structure and the 5' regulatory sequences, and including a SV40 splice and polyadenylation signal (Toggas et al., 1994) . The resulting plasmid was cut with S®I, releasing the linearized GFAP ± Y236D transgene which was sent to BRL (FuÈ llinsdorf, Switzerland) for microinjection into BDF2 fertilized eggs. The transgenic ospring was backcrossed to DBA/2 mice until the genetic background reached at least 7/8 DBA/2 (7/8 DBA/2, 1/8 C57BL/6). All mice in the experiment were kept in an SPF-facility (speci®ed pathogen free).
Genomic analysis of transgenic mice
The presence of the transgene was determined by PCR using a forward primer 155-E1-s (Weissenberger et al., 1997) located in exon 1 of the GFAP gene and a reverse primer (157-p53/GFAP-R: 5'-GAC GCT AGG ATC TGA CTG CG-3') located in the human p53 gene which result in a 425 bp PCR-product. The copy number and the number of integration sites of the transgene were investigated by Southern analysis. Ten mg of DNA were digested with BamHI or PvuII, respectively, separated on a 0.7% agarose gel, and blotted onto a Hybond-N + membrane (Amersham, UK) under alkaline conditions. Hybridization to radiolabeled ( 32 P) human p53 cDNA [BamHI fragment of pC53-SN3, (Baker et al., 1990) ] or mouse p53 cDNA (Pennica et al., 1984) was performed in Church buer (0.5 M Sodium phosphate buer pH 7.2, 7% SDS, 1 mM EDTA) at 658C overnight. The membranes were washed under stringent conditions (0.1% SDS, 0.16SSC, 608C).
Expression of the transgene
Expression of the transgene was analysed by Northern blot analysis using 10 mg total RNA isolated by Rneasy-kit (Qiagen). The RNA was separated on a 1% agarose gel containing formaldehyde, transferred onto a Hybond-N membrane (Amersham) in 206SSC, and UV-crosslinked. To control for equal loading and to con®rm the quality of the RNA, the membrane was stained with methylene blue. The membranes were hybridized to radiolabeled ( 32 P) human p53 cDNA and to GFAP cDNA (kind gift from U Pott, Brain Research Institute, University of Zurich).
To increase the sensitivity, expression of the transgene was analysed by RT ± PCR. Total RNA was treated with two units DNase for 30 min in a volume of 50 ml (6 mM MgCl 2 , 10 mM DTT, 100 units RNase inhibitor, TE pH 7.4), precipitated, and resuspended in water. One mg of total RNA was used in the RT-reaction in a volume of 20 ml using random hexamer primers and MMLV reverse transcriptase. Five ml of the RT-reaction were used for subsequent PCR with 30 cycles. Expression of the transgene was determined using the primers for genotype analysis (155-E1-s and 157-p53/GFAP-R); the spliced transgene yields a 338 bp product. The primers for GFAP and b-actin have been described before (Weissenberger et al., 1997) .
Induction of transgene expression by cryo-lesions
All animal experiments were approved and conformed to the guidelines set by the Institutional Animal Care Committee. Transgenic mice and wild-type littermates were anesthetized, placed in a stereotaxic frame (Narashige, Tokyo, Japan), and a small incision of the skin was made near the bregma. A cooled metal device (2 mm diameter) ®xed in the needle opening of a 50 ml syringe ®lled with liquid nitrogen was placed directly on the scull for 30 s (coordinates: bregma 0/0, right +1.5 mm). Animals were killed 16, 24, 48, 72 h, or 7 and 21 days after lesioning.
Brain tumor induction with ENU
Female GFAP-Y236D transgenic mice were mated with p53 7/7 mice (15/16 C57BL/6, 1/16 129Sv) (Donehower et al., 1992) or p53 +/+ C57BL/6 mice. Crosses were done in order to obtain the desired combination of the transgene and p53 knock-out alleles (Table 1) . Care was taken to have mice in the experiment with a similar, informative genetic background. On day 13.5 or 14.5, of gestation pregnant mice were injected i.p. with ENU (25 mg/kg BW; Sigma, N3385). ENU was dissolved in 0.05% acetic acid, 0.9% NaCl immediately before injection in order to prevent decay which occurs very rapidly at neutral pH. The ospring was analysed for the transgene as described above and genotyped for endogenous p53 using the primers and PCR strategy published (Timme and Thompson, 1994) . The ENU-treatment had no eect on litter size or on the ratio of female to male ospring. Mice were closely monitored for signs of neurological symptoms. Animals were sacri®ced when symptomatic or at the end of the experiment at the age of 58 weeks. Before necropsy mice were injected twice with bromodeoxyuridine (BrdUrd). Macroscopically visible brain tumors were divided to be snap frozen and ®xed for histology.
Immunohistochemistry and tumor classification
Brains were ®xed for 4 ± 16 h in 4% buered paraformaldehyde, rinsed in water, and cut in ®ve parts prior to paran embedding. Paran sections were stained for expression of GFAP using a polyclonal antibody (DAKO, Glostrup, Denmark) and for human p53 protein using PAb1801 (GENOSYS, Cambridgeshire, UK) which is speci®c for human p53. Selected brains were analysed for BrdUrd incorporation (anti-BrdUrd antibody; Caltag Lab, San Francisco, USA). Double immunostaining for GFAP and human p53 was performed using the antibodies GP52 (PROGEN, Readysysteme AG, Zurzach, Switzerland) and the FITC labeled PAb1801 (Novocastra, Readysysteme AG), respectively. The tumors were classi®ed according to the WHO guidelines (Kleihues and Cavenee, 2000) although murine tumors do not exactly ®t the nomenclature for human tumors. All macroscopically visible extracerebral lesions were prepared for histologic evaluation. In addition, when animals showed signs of paresis the spine was subjected to histological analysis after ®xation and decalci®cation as described previously (Maddalena et al., 1999) .
Microsatellite analysis of the tumors
The tumors and respective normal tissues were microdissected on paran slides and subjected to allelotype analysis using microsatellites located in the vicinity of the mouse p53 gene in order to determine the presence of the endogenous p53 alleles. The microsatellite markers used were D11Mit90 and D11Mit279, which are located within 1 to 2 cM from p53, and D11Mit82, which is located 47 cM proximal to p53 in the vicinity of the epidermal growth factor receptor gene (http://www-genome.wi.mit.edu; http://www.informatics.jax. org). In addition, the following microsatellites were used: D7Mit291, D7Mit333, and D7Mit334, spanning the mouse homologous region to 10q25.3-q26 in humans that harbors the DMBT1 gene; D19Mit13 and D19Mit80 in the vicinity of the pten gene (Di Cristofano et al., 1998) ; Mts1 in the p16 gene (Patel et al., 2000) ; and D14Nki located in intron 21 of the Rb-1 gene (Groot et al., 1992) . The primers were ordered from Research Genetics (Huntsville, AL, USA) or Microsynth (Balgach, Switzerland), and PCR was performed using 2 ml of crude tissue digest as described previously (Maddalena et al., 1999) . The PCR-products were separated on 2 ± 4% agarose gels (NuSieve 3 : 1) containing ethidiumbromide.
